Venture • Life Science

General Atlantic Invests In Third Harmonic Bio

On February 16, 2022, growth capital firm General Atlantic invested in life science company Third Harmonic Bio

Investment Context
  • This is General Atlantic’s 16th transaction in the Life Science sector.
  • This is General Atlantic’s 152nd transaction in the United States.
  • This is General Atlantic’s 43rd transaction in California.
Investment Fate
  • Third Harmonic Bio went public in 2022.

Explore All 557 Venture Life Science Deals - Search the Database Free


Investment Summary

Date February 16, 2022
Target Third Harmonic Bio
Sector Life Science
Investor(s) General Atlantic
Deal Type Venture

Target Company

Third Harmonic Bio

San Francisco, California, United States
Third Harmonic Bio is a clinical stage bio technology company developing an oral KIT inhibitor therapy for allergic autoimmune disorders. Third Harmonic Bio was founded in 2019 and is based in San Francisco, California.
Explore More Deals

Browse All 215,130 Deals

FILTER BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Search Free

Investor Overview 1

Investor

General Atlantic

Investor Investor Investor Investor Investor


Category Growth Capital Firm
Founded 1980
PE ASSETS 105.0B USD
Size Mega
Type Sector Agnostic
DESCRIPTION

General Atlantic is a large private equity firm that invests globally in growth-oriented public and private companies. Broad areas of interest include financial services, media and consumer, healthcare, enterprise solutions, communications and electronics, and energy. General Atlantic looks to invest $40 to $400 million in transactions that support growth, expansions, buy-outs, consolidations and build-ups. General Atlantic seeks to make 8 to 12 investments per year with an investment horizon of five to ten years. The Firm's geographic coverage spans North America; Europe; Asia/Pacific; and India. General Atlantic was formed in 1980 and is based in New York, New York.


Deal Context for Investor #
Overall 319 of 364
Sector: Life Science 16 of 20
Type: Venture 93 of 98
State: California 43 of 47
Country: United States 152 of 175
Year: 2022 9 of 24
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-02-07 Reliance Health

Lagos, Nigeria

Reliance Health is a healthcare company using technology to make healthcare more affordable and accessible. Using an integrated approach that includes affordable health insurance, telemedicine, and a combination of partner and proprietary healthcare facilities. Reliance Health was founded in 2015 and is based in Lagos, Nigeria.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-03-09 Branch

Minneapolis, Minnesota, United States

Branch is a workforce payments platform that partners with businesses to accelerate payments and empower working Americans. Businesses turn to Branch for a more cost-effective, faster way to pay workers and reduce the costs of paper checks and pay cards. Branch was founded in 2015 and is based in Minneapolis, Minnesota.

Buy -